Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells.
J Cell Mol Med
; 26(1): 228-234, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1532813
ABSTRACT
The outbreak of COVID-19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID-19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS-CoV-2 entry has been detected in all MSC samples. These results are of particular importance for future MSC-based cell therapies to treat severe cases after COVID-19 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cell Transplantation
/
Spike Glycoprotein, Coronavirus
/
Cell- and Tissue-Based Therapy
/
Cytokine Release Syndrome
/
Angiotensin-Converting Enzyme 2
/
SARS-CoV-2
/
COVID-19
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
J Cell Mol Med
Journal subject:
Molecular Biology
Year:
2022
Document Type:
Article
Affiliation country:
Jcmm.17048
Similar
MEDLINE
...
LILACS
LIS